Claims:

1. A method of treating an intrahepatic cholestatic disease by administering MBX-8025 or an MBX-8025 salt.

2. MBX-8025 or an MBX-8025 salt for use in treating an intrahepatic cholestatic disease.

3. The use of MBX-8025 or an MBX-8025 salt for treating an intrahepatic cholestatic disease.

4. The use of MBX-8025 or an MBX-8025 salt in the manufacture of a medicament for treating an intrahepatic cholestatic disease.

5. A pharmaceutical composition comprising MBX-8025 or an MBX-8025 salt for treating an intrahepatic cholestatic disease.

6. A kit for treating an intrahepatic cholestatic disease comprising a composition comprising MBX-8025 or an MBX-8025 salt.

7. The method, compounds, uses, composition, or kit of any one of the previous claims where the MBX-8025 or an MBX-8025 salt is MBX-8025 L-lysine dihydrate salt.

8. The method, compounds, uses, composition, or kit of any one of the previous claims where the MBX-8025 or an MBX-8025 salt is administered orally.

9. The method, compounds, uses, composition, or kit of any one of the previous claims where the daily dose of MBX-8025 or an MBX-8025 salt (when calculated as the free acid) is 20-200 mg/day, preferably 50-100 mg/day.

10. The method, compounds, uses, composition, or kit of any one of the previous claims where the MBX-8025 or an MBX-8025 salt is administered once/day.

11. The method, compounds, uses, composition, or kit of any one of the previous claims where the intrahepatic cholestatic disease is primary biliary cirrhosis.

12. The method, compounds, uses, composition, or kit of any one of the previous claims where the intrahepatic cholestatic disease is primary sclerosing cholangitis.

13. The method, compounds, uses, composition, or kit of any one of the previous claims where the intrahepatic cholestatic disease is progressive familial intrahepatic cholestasis.

14. The method, compounds, uses, composition, or kit of any one of the previous claims where the intrahepatic cholestatic disease is Alagille syndrome.

5

Claims:

1. The use of a compound that is *(R)*-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy)-propyl)thio)-2-methylphenoxy)acetic acid or a salt thereof in the manufacture of a medicament for treating an intrahepatic cholestatic disease.

2. The use of claim 1 where the compound is *(R)*-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)-phenoxy)propyl)thio)-2-methylphenoxy)acetic acid l-lysine dihydrate.

3. The use of claim 1 or 2 where the compound is administered orally.

4. The use of any one of claims 1 to 3 where the dose of the compound is 20-200 mg/day when the dose of the compound is calculated as *(R)*-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy)acetic acid.

5. The use of claim 4 where the dose of the compound is 50-200 mg/day when the dose of the compound is calculated as *(R)*-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy)acetic acid.

6. The use of any one of the previous claims where the compound is administered once/day.

7. The use of any one of claims 1 to 6 where the intrahepatic cholestatic diseases is primary biliary cirrhosis, primary sclerosing cholangitis, progressive familial intrahepatic cholestasis, or Alagille syndrome.

8. The use of claim 7 where the intrahepatic cholestatic disease is primary biliary cirrhosis.

9. The use of claim 7 where the intrahepatic cholestatic disease is primary sclerosing cholangitis.

10. The use of claim 7 where the intrahepatic cholestatic disease is progressive familial intrahepatic cholestasis.

11. The use of claim 7 where the intrahepatic cholestatic disease is Alagille syndrome.